Dabrafenib (GSK2118436)

Name: Dabrafenib (GSK2118436)
Brand: Selleck Chemicals
SKU: S2807
Rating: 5 (157 reviews)

For research use only.

Catalog No.S2807

157 publications

Dabrafenib (GSK2118436) Chemical Structure

CAS No. 1195765-45-7

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Selleck's Dabrafenib (GSK2118436) has been cited by 157 publications

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2018, 8(4):417-427

PubMed: 29431697 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Cancer Cell, 2016, 12;30(3):485-498

PubMed: 27523909 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202004707

PubMed: 32561648 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Cancers (Basel), 2020, 22;12(2) pii: E512

PubMed: 32098410 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Sci Rep, 2020, 8;10(1):7826

PubMed: 32385388 ( click the link to review the publication )

Sci Rep, 2020, 27;10(1):5557

PubMed: 32221312 ( click the link to review the publication )

J Biol Chem, 2020, 295(8):2407-2420

PubMed: 31929109 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Front Chem, 2020, 23;8:184

PubMed: 32266211 ( click the link to review the publication )

Pathol Oncol Res, 2020, 10.1007/s12253-020-00834-y

PubMed: 32591993 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Br J Cancer, 2020, 122(6):789-800

PubMed: 31932756 ( click the link to review the publication )
Biology (Basel), 2020, 9(8):E218

PubMed: 32785105 ( click the link to review the publication )

ESMO Open, 2020, 5(4):e000707

PubMed: 32817058 ( click the link to review the publication )

Neoplasia, 2020, 22(9):376-389

PubMed: 32629178 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3946

PubMed: 32770055 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):387-402

PubMed: 32142667 ( click the link to review the publication )

Acta Neuropathol Commun, 2020, 8(1):139

PubMed: 32811569 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0298-5

PubMed: 30742091 ( click the link to review the publication )

Eur J Cancer, 2019, 109:137-153

PubMed: 30721788 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):272

PubMed: 31227006 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31533235 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):119

PubMed: 31345255 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )
J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113616

PubMed: 31445021 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1225

PubMed: 30718660 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:223

PubMed: 31467489 ( click the link to review the publication )

Surgery, 2019, 10.1016/j.surg.2019.04.076

PubMed: 31585718 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Metabolites, 2019, 9(11)

PubMed: 31744229 ( click the link to review the publication )

Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

Reprod Domest Anim, 2019, 54(5):741-749

PubMed: 30785650 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10865

PubMed: 31350469 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31783660 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):275-286

PubMed: 31874374 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )

Mol Cell, 2018, 70(5):920-935

PubMed: 29883609 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )
Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2500

PubMed: 29950559 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1466

PubMed: 29654229 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(14):3377-3385

PubMed: 29650750 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(22):3974-3985

PubMed: 30137437 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9991

PubMed: 29968772 ( click the link to review the publication )

Front Pharmacol, 2018, 9:856

PubMed: 30154717 ( click the link to review the publication )

ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36503-36514

PubMed: 30559933 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):325

PubMed: 29487283 ( click the link to review the publication )

Oncotarget, 2018, 9(17):13324-13336

PubMed: 29568360 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )
Sci Rep, 2018, 8(1):10724

PubMed: 30013176 ( click the link to review the publication )

NPJ Syst Biol Appl, 2018, 4:39

PubMed: 30416750 ( click the link to review the publication )

Oncoimmunology, 2018, 8(1):e1512456

PubMed: 30546949 ( click the link to review the publication )

Cell Syst, 2018, 7(2):161-179

PubMed: 30007540 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Neural Regen Res, 2018, 13(2):252-256

PubMed: 29557374 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4684-4696

PubMed: 28652244 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(19):3631-3645

PubMed: 28551825 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15523

PubMed: 29138474 ( click the link to review the publication )

Anal Bioanal Chem, 2017, 409(15):3749-3756

PubMed: 28429064 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2741-2751

PubMed: 29048639 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68208-68220

PubMed: 28978109 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )

Cell Death Differ, 2017, 24(1):83-97

PubMed: 27834956 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(29):E5930-E5939

PubMed: 28684402 ( click the link to review the publication )
Int J Mol Sci, 2017, 18(10)

PubMed: 29064427 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Blood Adv, 2017, 30;1(24):2147-2160

PubMed: 29296862 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(10):1776-1790

PubMed: 27464255 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

J Biol Chem, 2016, 291(34):17804-15

PubMed: 27226552 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Sci Rep, 2016, 6:23713

PubMed: 27025703 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75839-75853

PubMed: 27713119 ( click the link to review the publication )

Oncotarget, 2016, 7(12):15065-92

PubMed: 26918341 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(8):2021-2030

PubMed: 25748555 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Eur J Pharmacol, 2015, 762:283-92

PubMed: 26048310 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )
PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Cancer Res, 2015, 75(1):216-29

PubMed: 25381152 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(12):1934-7

PubMed: 26443648 ( click the link to review the publication )

Oncotarget, 2015, 6(38):40535-56

PubMed: 26497853 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(6):602-9

PubMed: 25795007 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Targets

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-Raf^V600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-Raf^V600E. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	NEfZV2JMcW6jc3WgRZN{[Xl?				M2HBRmlvcGmkaYTpc44hd2ZiTj30[ZJucW6jbDDIbZMhfGGpZ3XkJGIuWmGoIG[2NFBGKG23dHHueEBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IHPlcIx{KGOxLXX4dJJme3OrbnegR2REOzdiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[mmxdHnufYxifGWmLV3FT{Bxem:2ZXnuJJBpd3OyaH;yfYxifGmxbjDifUBCdHCqYWPjdoVmdiCjc4PhfUB4cXSqIFnDOVAhd2ZiMD6wNFA4KM7:TR?=	NY\uTlV[OjR7MEC2O\|M>
SK-MEL-28	NV3IZXFnU2mwYYPlJGF{e2G7		MV6xJIg>		NFjpcG9KdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDTT{1OTUxvMkigZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hTVKNIIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xODRizszN	NITqSIEzPDlyME[3Ny=>
HepG2	MlznT4lv[XOnIFHzd4F6				M2n2PWlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIFjldGczKGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIFXST{BxcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEC0JO69VQ>?	M2PIRVI1QTByNkez
COLO205	M2rxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjvTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRMkC1JINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFch\|ryP	M{DybFI1QTByNkez
HepG2	NWDMS5JrTnWwY4Tpc44hSXO\|YYm=		NFvVNpU1PSCvaX6=	Mk[zSG1UVw>?	MnKyTY5pcWKrdHnvckBw\iCDbHu1JIlvKFSJRj3i[ZRiNXO2aX31cIF1\WRiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hW22jZEKgdIhwe3Cqb4L5cIF1cW:wIITy[YF1\WRiZn;yJFQ2KG2rboOgdJJqd3JidH:gWGdHNWKndHGgd5RqdXWuYYTpc44hdWWjc4Xy[YQh[W[2ZYKgOlAhdWmwczDifUBw\Hm\|c3X5JIJtd3Ric3Phco5meiCjbnHsfZNqeyC5aYToJGlEPTBib3[gN{44KM7:TR?=	NInLO4EzPDlyME[3Ny=>
HFF	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU[xNEDPxE1?	M{GycFczKGh?	Moe5SG1UVw>?	NV;FVXBDUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIHj1cYFvKEiIRjDj[YxteyCqYYLic5Jqdmdid3ns[EB1gXCnIFKtVoFnKHerdHigTWM2OCCxZjCzJO69VQ>?	M1;mO\|I{QDR2MEO4
SK-MEL-28	NX35XopzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3K5b\|ExKM7:TR?=	MXO3NkBp	M3XoU2ROW09?	NUi0T2Y{UW6qaXLpeIlwdiCxZjDCMXJi\iCYNkCwSUBufXSjboSt[JJqfmWwIGPLMW1GVC1{ODDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMESzJO69VQ>?	NXrVVppsOjN6NESwN\|g>
A375P-F11	M1XxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHPNVAh\|ryP	MofMO\|IhcA>?	MVnEUXNQ	NWj1UZdTUW6qaXLpeIlwdiCxZjDCMXJi\iCYNkCwSUBufXSjboSt[JJqfmWwIFGzO\|VRNUZzMTDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEexJO69VQ>?	MY[yN\|g1PDB\|OB?=
MALME-3M	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHr3NZAyOCEQvF2=	NETwTWI4OiCq	MlXoSG1UVw>?	M3iye2lEPTB;MTDuUS=>	NF\HdnozOzh2NECzPC=>
UACC-62	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXOxNEDPxE1?	NUDp[G02PzJiaB?=	MVPEUXNQ	NUDlb2tbUUN3ME2xJI5O	M{DvfVI{QDR2MEO4
C32TG	NYnrfYdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1T0[VExKM7:TR?=	M2HwXVczKGh?	NGPnRYRFVVOR	NXvhRVd5UUN3ME2xJI5O	NEK1UXIzOzh2NECzPC=>
SK-MEL-1	NHHwUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV2xNEDPxE1?	M4XpN\|czKGh?	Mlz6SG1UVw>?	NIni[HNKSzVyPUKgcm0>	M{D1VlI{QDR2MEO4
M14	M2rUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jxZVExKM7:TR?=	NFjZXY04OiCq	NEjuSW1FVVOR	MYrJR\|UxRTJibl2=	M4jPS\|I{QDR2MEO4
SK-MEL-28	NInWWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LrcFExKM7:TR?=	NGfrO2Q4OiCq	NFy1PGZFVVOR	NGK3e2JKSzVyPUOgcm0>	MUiyN\|g1PDB\|OB?=
A375	NV7nVopxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4r5VlExKM7:TR?=	Ml;TO\|IhcA>?	NY[4SFd2TE2VTx?=	NX\pdFBMUUN3ME20JI5O	NYL6VXJuOjN6NESwN\|g>
DU-4475	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\IN\|ExKM7:TR?=	M4\XWlczKGh?	M2PhXWROW09?	MYjJR\|UxRTVibl2=	MUWyN\|g1PDB\|OB?=
UACC-257	NVziOoRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVm0S3hyOTBizszN	NXX3VXluPzJiaB?=	NYXibmMyTE2VTx?=	NGXSWHBKSzVyPU[gcm0>	MoK4NlM5PDRyM{i=
Colo 205	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrjWZp7OTBizszN	M3zKO\|czKGh?	M3LGZ2ROW09?	Mmf1TWM2OD15IH7N	NUHjNIdDOjN6NESwN\|g>
SK-MEL-3	NH7vXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV:xNEDPxE1?	Ml;IO\|IhcA>?	NYCwbWdGTE2VTx?=	Mlq2TWM2OD15IH7N	M2KzZVI{QDR2MEO4
SH-4	MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHrZ\|gyOCEQvF2=	NV7ZfGp2PzJiaB?=	Mn;iSG1UVw>?	NHfmXFVKSzVyPUigcm0>	NV;SfpNMOjN6NESwN\|g>
A101D	NHP2R3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWOxNEDPxE1?	NFvSc4g4OiCq	NH7o[nlFVVOR	MoTMTWM2OD17IH7N	NYXp[WNtOjN6NESwN\|g>
ES-2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fkeVExKM7:TR?=	M4LO[VczKGh?	NGnJO4pFVVOR	NGj5PYRKSzVyPUWzJI5O	M3G5SlI{QDR2MEO4
HT-29	NF:xd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PxXVExKM7:TR?=	MX63NkBp	MonlSG1UVw>?	NGrGe4VKSzVyPU[2JI5O	NEK1WpMzOzh2NECzPC=>
SW1417	NYjQb\|BnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUGxNEDPxE1?	Mm\0O\|IhcA>?	MYLEUXNQ	MmfqTWM2OD1zNUigcm0>	MoDJNlM5PDRyM{i=
SW872	M2[yWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4r1b\|ExKM7:TR?=	M1q2b\|czKGh?	M2DVNmROW09?	Mlu0TWM2OD1\|N{egcm0>	MnPmNlM5PDRyM{i=
RKO	NXHPTmNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvyTmNROTBizszN	MWi3NkBp	NES1WmtFVVOR	NEfEdGhKSzVyPUKuOVIzKM7:TR?=	Mlj4NlM5PDRyM{i=
A673	NVv6Z4RtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{[zRlExKM7:TR?=	MXu3NkBp	MnHOSG1UVw>?	MmH6TWM2OD1zMDFOwG0>	NXz0dlVuOjN6NESwN\|g>
GCT	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWizNoZ3OTBizszN	MWi3NkBp	NF3oboRFVVOR	M3XDWmlEPTB;MUCg{txO	MV2yN\|g1PDB\|OB?=
WM-115	MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVKxNEDPxE1?	NIXESIE4OiCq	M{Thd2ROW09?	NHHLeJRKSzVyPUWgcm0>	MmTPNlM5PDRyM{i=
YUMAC	MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfFNVVOOTBizszN	NVvwRZdjPzJiaB?=	M2PHSWROW09?	MmXVTWM2OD13IH7N	NHPW[lUzOzh2NECzPC=>
OV-90	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLwdIR5OTBizszN	NY\QW2VUPzJiaB?=	MUTEUXNQ	M{OyWWlEPTB;Mkmgcm0>	Mo\hNlM5PDRyM{i=
NCI-H508	M{e4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3PNVAh\|ryP	NHjVc2s4OiCq	NIW1RpZFVVOR	NG\jbXNKSzVyPUGwJO69VQ>?	NH\p[ZczOzh2NECzPC=>
MDA-MB-231	NH76OGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXexNEDPxE1?	NFq1OYI4OiCq	MmrnSG1UVw>?	Mke5TWM2OD1zMDFOwG0>	M2[0elI{QDR2MEO4
SW756	NFTxdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkj2NVAh\|ryP	MlTYO\|IhcA>?	NGW1N3lFVVOR	M1z1NWlEPTB;MUCg{txO	NXezN5lFOjN6NESwN\|g>
SW-837	NHj3R5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLTNodROTBizszN	NIC4ZZI4OiCq	M2XJXWROW09?	NVryTmNwUUN3ME2xNEDPxE1?	MUSyN\|g1PDB\|OB?=
UMUC-3	M2XvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDhW2UyOCEQvF2=	NHToeXM4OiCq	M{S2UGROW09?	MkT6TWM2OD1zMDFOwG0>	M1TySlI{QDR2MEO4
LS-174T	NUnCWmpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXWxNEDPxE1?	MWS3NkBp	NH;XfndFVVOR	NEizRmZKSzVyPUGwJO69VQ>?	MYWyN\|g1PDB\|OB?=
A549	NGXOeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDsN28yOCEQvF2=	MVu3NkBp	NILyVXBFVVOR	MkK5TWM2OD1zMDFOwG0>	MYqyN\|g1PDB\|OB?=
SHP-77	NF:0OnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEW3RocyOCEQvF2=	NF\sVJI4OiCq	MWPEUXNQ	Mn3yTWM2OD1zMDFOwG0>	MnjYNlM5PDRyM{i=
SW480	NGO0THJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYSwbFhZOTBizszN	MkHvO\|IhcA>?	NH3E[lZFVVOR	M{DldGlEPTB;MUCg{txO	NGjtN20zOzh2NECzPC=>
DLD-1	MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXmxNEDPxE1?	MkXVO\|IhcA>?	NH;BR25FVVOR	Ml6xTWM2OD1zMDFOwG0>	NH3BUokzOzh2NECzPC=>
HCT-116	MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLO[4YyOCEQvF2=	MWi3NkBp	NFqzTndFVVOR	M4TDe2lEPTB;MUCg{txO	M3T0dlI{QDR2MEO4
NCI-H747	NUfybW93T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVSxNEDPxE1?	M1[xTlczKGh?	NIDYUYhFVVOR	M1;ZXGlEPTB;MUCg{txO	NHXGXVUzOzh2NECzPC=>
T-84	NWi5Roh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XGV\|ExKM7:TR?=	NEDKc404OiCq	NHW5d\|BFVVOR	NWfaSI5DUUN3ME2xNEDPxE1?	NFHjWW0zOzh2NECzPC=>
NCI-H460	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPtc3UyOCEQvF2=	MWi3NkBp	NGL4W2lFVVOR	MkH3TWM2OD1zMDFOwG0>	M3;IelI{QDR2MEO4
Calu-6	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDTUZoyOCEQvF2=	NIm0NnY4OiCq	MVvEUXNQ	NWTQPGF4UUN3ME2xNEDPxE1?	NUP1SJBJOjN6NESwN\|g>
HCC-2998	NYjkXGpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfYblREOTBizszN	MonOO\|IhcA>?	M1noZWROW09?	M1nlZmlEPTB;MUCg{txO	M1y5e\|I{QDR2MEO4
LS1034	NYG1NmdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHQbFkyOCEQvF2=	MVi3NkBp	MkXnSG1UVw>?	MWfJR\|UxRTFyIN88US=>	MoThNlM5PDRyM{i=
CHP-212	NWPvSXl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjpXYN4OTBizszN	MVO3NkBp	NEnldJZFVVOR	NFLIc4hKSzVyPUGwJO69VQ>?	MmPqNlM5PDRyM{i=
SK-N-AS	NG\sd29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrkV3YyOCEQvF2=	M3fuSVczKGh?	MUTEUXNQ	MmDnTWM2OD1zMDFOwG0>	MlnxNlM5PDRyM{i=
BFTC-905	NVvoO4JbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPqNVAh\|ryP	NXPRXGdIPzJiaB?=	NYnWZZRiTE2VTx?=	NIrHXnhKSzVyPUGwJO69VQ>?	MmriNlM5PDRyM{i=
HuT78	NYPoUWRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Hib\|ExKM7:TR?=	M3zyVlczKGh?	NU\6b4F4TE2VTx?=	M3\TNWlEPTB;NUKgcm0>	Mk\mNlM5PDRyM{i=
RPMI-8226	MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGS1docyOCEQvF2=	M4ftTlczKGh?	NVnhd3RtTE2VTx?=	M{LTNWlEPTB;Mk[zJI5O	M3XHXVI{QDR2MEO4
BC-3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfiWHQyOCEQvF2=	NEnvSlQ4OiCq	M1jOfGROW09?	NGrEU5hKSzVyPUK3O{BvVQ>?	M1TESFI{QDR2MEO4
ACHN	MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF75T4gyOCEQvF2=	NF75OFE4OiCq	MonMSG1UVw>?	MXXJR\|UxRTJ7NDDuUS=>	NW\aNnBKOjN6NESwN\|g>
JRT3-T35	M1HoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{niOVExKM7:TR?=	MVe3NkBp	M{H1e2ROW09?	NH\TcnBKSzVyPUK5OUBvVQ>?	NXHaOG5IOjN6NESwN\|g>
SK-MES-1	MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULOSlJ6OTBizszN	M1f2TVczKGh?	M2nGRmROW09?	NYXRd\|BNUUN3ME2zNlkhdk1?	MlvvNlM5PDRyM{i=
CESS	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvENVAh\|ryP	NWC3NFRtPzJiaB?=	NIPiUnRFVVOR	NYWxclBKUUN3ME20PVchdk1?	NEDGfIkzOzh2NECzPC=>
H4	NH\n[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUCxNEDPxE1?	M3XrR\|czKGh?	Mkj3SG1UVw>?	MnjITWM2OD14MUmgcm0>	MYOyN\|g1PDB\|OB?=
BC-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nSTFExKM7:TR?=	NYD4[mtPPzJiaB?=	MonQSG1UVw>?	MlvQTWM2OD15MESgcm0>	M17z[lI{QDR2MEO4
DB	NVj6TFFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfyTZoyOCEQvF2=	MXO3NkBp	NWjyWIV6TE2VTx?=	MVjJR\|UxRTh5MzDuUS=>	M{XjUlI{QDR2MEO4
RPMI-6666	M2XKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX2xNEDPxE1?	MnXhO\|IhcA>?	NX7zXnpETE2VTx?=	MWLJR\|UxRTl{ODDuUS=>	NWjKTXNPOjN6NESwN\|g>
MC/CAR	M4\yfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLBNVAh\|ryP	MV63NkBp	NXvFTlV1TE2VTx?=	MoLYTWM2OD1zLkCwNkDPxE1?	MmjMNlM5PDRyM{i=
SNU-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjZOWoyOCEQvF2=	Mmm5O\|IhcA>?	MmHESG1UVw>?	MmTQTWM2OD1zLkWwNUDPxE1?	NVrrdlZKOjN6NESwN\|g>
CEM/C1	NV7ofYFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXCNVAh\|ryP	NX3kdGVJPzJiaB?=	MX;EUXNQ	M1XCRmlEPTB;MT63O\|Mh\|ryP	NXL0NI1DOjN6NESwN\|g>
GDM-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfZW2EyOTBizszN	NGfFUXQ4OiCq	NVfaR3pKTE2VTx?=	MXjJR\|UxRTFwOUm3JO69VQ>?	M3P5fVI{QDR2MEO4
HT-1080	M2fjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnmNVAh\|ryP	NHy5Wno4OiCq	NHewc5ZFVVOR	NWHMRoV2UUN3ME2yMlAxPCEQvF2=	NXrDRnBPOjN6NESwN\|g>
HL-60	M1zUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLUNVAh\|ryP	NIrISVY4OiCq	NHvxZZhFVVOR	MlfJTWM2OD1{LkG3PEDPxE1?	NH20UokzOzh2NECzPC=>
C3A	NIP2XIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXmxNEDPxE1?	NV\FVIZDPzJiaB?=	M1PKXWROW09?	NFmzc4VKSzVyPUWuOFE1KM7:TR?=	MlvuNlM5PDRyM{i=
MES-SA	Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoD5NVAh\|ryP	M1fOb\|czKGh?	M1q3NWROW09?	M2LzZmlEPTB;Nj65PFkh\|ryP	NGjTN\|UzOzh2NECzPC=>
22Rv1	M{ixO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnH0NVAh\|ryP	M3HY[FczKGh?	MlXPSG1UVw>?	NH:zWXlKSzVyPUGwJO69VQ>?	MUiyN\|g1PDB\|OB?=
647-V	M4HDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWCxNEDPxE1?	NGDU[nE4OiCq	NYnyS4ZoTE2VTx?=	M1\hTWlEPTB;MUCg{txO	NXLwNZF3OjN6NESwN\|g>
786-O	MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TyZlExKM7:TR?=	M1zqUVczKGh?	NXv6VVdPTE2VTx?=	NIqxbIRKSzVyPUGwJO69VQ>?	M4PwSVI{QDR2MEO4
A172	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXixNEDPxE1?	MXi3NkBp	NI\JTIJFVVOR	M1LxR2lEPTB;MUCg{txO	NUK3eWJrOjN6NESwN\|g>
A204	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoGzNVAh\|ryP	NGDKeII4OiCq	NGPBVIpFVVOR	M3XsUmlEPTB;MUCg{txO	NYfCW3c{OjN6NESwN\|g>
A427	NIfYbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFq4S5QyOCEQvF2=	NVf2VIY1PzJiaB?=	NYXoVGoyTE2VTx?=	MXjJR\|UxRTFyIN88US=>	MWKyN\|g1PDB\|OB?=
A431	M1vhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\OclExKM7:TR?=	MlHvO\|IhcA>?	MVfEUXNQ	M3fHU2lEPTB;MUCg{txO	Mn\WNlM5PDRyM{i=
A2780	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUexNEDPxE1?	NF7Q[Jo4OiCq	NETORphFVVOR	NGrSRlFKSzVyPUGwJO69VQ>?	M17ScVI{QDR2MEO4
ARH-77	Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\5VVBnOTBizszN	MXe3NkBp	MonsSG1UVw>?	NULTeI11UUN3ME2xNEDPxE1?	MVKyN\|g1PDB\|OB?=
Be(2)C	Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vYdFExKM7:TR?=	M3\zelczKGh?	NVHV[plLTE2VTx?=	NYH0bGc5UUN3ME2xNEDPxE1?	NYrxe4ExOjN6NESwN\|g>
BT-20	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjtOoEyOCEQvF2=	NWG3[JVuPzJiaB?=	MoPrSG1UVw>?	M4rnfmlEPTB;MUCg{txO	MXmyN\|g1PDB\|OB?=
BxPc3	M2mxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX:xNEDPxE1?	MW[3NkBp	NU\MN3pETE2VTx?=	MYTJR\|UxRTFyIN88US=>	MkDLNlM5PDRyM{i=
C-4 I	NH\KZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjyO4lzOTBizszN	M3f5O\|czKGh?	M2\JVmROW09?	MkXDTWM2OD1zMDFOwG0>	NWjWRmVpOjN6NESwN\|g>
C33A	Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUSxNEDPxE1?	MYK3NkBp	MUfEUXNQ	NX3zUoVYUUN3ME2xNEDPxE1?	MVSyN\|g1PDB\|OB?=
CAL-27	M1TvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjqcXk1OTBizszN	M2fk[VczKGh?	NEDQfJdFVVOR	M3zFNGlEPTB;MUCg{txO	M{DBVVI{QDR2MEO4
CAL-62	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1L2d\|ExKM7:TR?=	Mnq5O\|IhcA>?	M4TzemROW09?	NHn2emZKSzVyPUGwJO69VQ>?	NUm1TFJwOjN6NESwN\|g>
Calu-3	Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mln3NVAh\|ryP	Ml7SO\|IhcA>?	NX\WWoFVTE2VTx?=	NHLmeYRKSzVyPUGwJO69VQ>?	NFPOOIYzOzh2NECzPC=>
CaOV3	M{DDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX2xNEDPxE1?	NVnTW3dEPzJiaB?=	NVjmcm5UTE2VTx?=	NX34TodZUUN3ME2xNEDPxE1?	MnvzNlM5PDRyM{i=
CGTHW1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfpNVAh\|ryP	MVm3NkBp	NVjoNZZ{TE2VTx?=	M1m3S2lEPTB;MUCg{txO	NUL6XlFiOjN6NESwN\|g>
CHL-1	NUD1UXhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLJT5o2OTBizszN	NX;nZYxmPzJiaB?=	MonDSG1UVw>?	M2rxUWlEPTB;MUCg{txO	MnzkNlM5PDRyM{i=
Colo320DM	M4HGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{KyUlExKM7:TR?=	NX7tcGpXPzJiaB?=	NWi1ZnhITE2VTx?=	M1zG[mlEPTB;MUCg{txO	NV70UW9DOjN6NESwN\|g>
Colo704	M1PET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jDflExKM7:TR?=	NUHCOpZtPzJiaB?=	NETzVIFFVVOR	M1PieGlEPTB;MUCg{txO	MVGyN\|g1PDB\|OB?=
COR-L23	NFz0O2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXX4ZWVCOTBizszN	NHKwR5M4OiCq	MX\EUXNQ	MmDRTWM2OD1zMDFOwG0>	NEjTVnozOzh2NECzPC=>
CRO-AP2	Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXEdVcyOCEQvF2=	MoPrO\|IhcA>?	NWnB[YNlTE2VTx?=	MoLOTWM2OD1zMDFOwG0>	NUfBOFNmOjN6NESwN\|g>
Daudi	M2Gx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXTWFMyOCEQvF2=	NGfyO3M4OiCq	NELGSolFVVOR	NYPvXYxbUUN3ME2xNEDPxE1?	M2G2dVI{QDR2MEO4
DOTC 24510	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHR[YkyOCEQvF2=	MYO3NkBp	Mkn6SG1UVw>?	NWG1OlhPUUN3ME2xNEDPxE1?	M2TxdFI{QDR2MEO4
DU-145	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX2xNEDPxE1?	MmDzO\|IhcA>?	NWrzOJg5TE2VTx?=	M3XPVmlEPTB;MUCg{txO	MlHhNlM5PDRyM{i=
EB-3	NEfSZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LHSFExKM7:TR?=	MUW3NkBp	NF3SZoRFVVOR	NULkfJJQUUN3ME2xNEDPxE1?	NHToNWkzOzh2NECzPC=>
EFM-19	NFjOZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUexNEDPxE1?	MmXLO\|IhcA>?	MmLVSG1UVw>?	MVnJR\|UxRTFyIN88US=>	NXO2VWdYOjN6NESwN\|g>
EKVX	MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrqPYgyOCEQvF2=	MofGO\|IhcA>?	M3q5d2ROW09?	M{fI[2lEPTB;MUCg{txO	NVu5TGlHOjN6NESwN\|g>
FaDu	M4T0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVmxNEDPxE1?	M4LKV\|czKGh?	MXLEUXNQ	Mn;UTWM2OD1zMDFOwG0>	NGTxfoszOzh2NECzPC=>
G401	M3vQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\xNVAh\|ryP	NIOxZWE4OiCq	MoLvSG1UVw>?	M2q3TWlEPTB;MUCg{txO	M1LETlI{QDR2MEO4
HCC-70	NVrhOZRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXOxNEDPxE1?	MYq3NkBp	NIrLc3VFVVOR	NWqxSWRlUUN3ME2xNEDPxE1?	M4rKbVI{QDR2MEO4
HCC-1954	NXTLTFlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jTSVExKM7:TR?=	NI\MXGI4OiCq	MY\EUXNQ	Mn[1TWM2OD1zMDFOwG0>	M3flNFI{QDR2MEO4
Hela	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUT5U3JMOTBizszN	NX[wT2l{PzJiaB?=	MoLTSG1UVw>?	NWHQ[\|AyUUN3ME2xNEDPxE1?	NIrI[G8zOzh2NECzPC=>
Hep3B	NYrnXlVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnQNVAh\|ryP	MXm3NkBp	NUP5NIVXTE2VTx?=	MlTvTWM2OD1zMDFOwG0>	Mn;MNlM5PDRyM{i=
HMCB	NYnRTppqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY[xNEDPxE1?	MXi3NkBp	M{PKTWROW09?	NHX6S3hKSzVyPUGwJO69VQ>?	M3zOeFI{QDR2MEO4
HN5	M3POW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDVZml6OTBizszN	M1jGdFczKGh?	MXPEUXNQ	M3HWUmlEPTB;MUCg{txO	M{XyTFI{QDR2MEO4
HOS	MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXINVAh\|ryP	MV63NkBp	MkD0SG1UVw>?	NF[5d4ZKSzVyPUGwJO69VQ>?	Mn[3NlM5PDRyM{i=
HPAF-II	NWrhcoRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DIOFExKM7:TR?=	M3rtWlczKGh?	NH:0SZJFVVOR	M{ToPWlEPTB;MUCg{txO	NXjjRVJROjN6NESwN\|g>
Hs746.T	NFXlfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUK5ToNZOTBizszN	NUX4XVhYPzJiaB?=	MVXEUXNQ	NEDMVYRKSzVyPUGwJO69VQ>?	NE\rfYczOzh2NECzPC=>
HT	NYfpcHQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DiRVExKM7:TR?=	M1;jRlczKGh?	M2TBUGROW09?	NYHySYJ7UUN3ME2xNEDPxE1?	MWKyN\|g1PDB\|OB?=
HT-3	M1rQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLLNVAh\|ryP	NYP3S5dSPzJiaB?=	NXG1c2w1TE2VTx?=	NWD3OZRSUUN3ME2xNEDPxE1?	Mni0NlM5PDRyM{i=
HuNS-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHPcXBYOTBizszN	NHqyO3A4OiCq	NIHyV5hFVVOR	MmqxTWM2OD1zMDFOwG0>	NWLjRY0{OjN6NESwN\|g>
IGROV1	Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX[xNEDPxE1?	NF\heJY4OiCq	M{POZ2ROW09?	M1TseWlEPTB;MUCg{txO	NYS0N5h5OjN6NESwN\|g>
J82	NF7v[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PqUVExKM7:TR?=	NX;ycJV3PzJiaB?=	NIfjSXBFVVOR	NVriSlhnUUN3ME2xNEDPxE1?	M3HmblI{QDR2MEO4
JM1	NX\pZXVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV:xNEDPxE1?	NXjmXVZUPzJiaB?=	NUX2NFFoTE2VTx?=	MoTFTWM2OD1zMDFOwG0>	MXmyN\|g1PDB\|OB?=
Kato III	NF7i[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlm4NVAh\|ryP	M2nwblczKGh?	NHXrbVVFVVOR	NGqyRXNKSzVyPUGwJO69VQ>?	MVGyN\|g1PDB\|OB?=
KHOS-240S	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrWdoQyOCEQvF2=	M{DmU\|czKGh?	NGDzc41FVVOR	MXHJR\|UxRTFyIN88US=>	MV2yN\|g1PDB\|OB?=
KM-12	NF7RcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrGbXhlOTBizszN	NWThe\|ljPzJiaB?=	M{D5V2ROW09?	NIG4SohKSzVyPUGwJO69VQ>?	NEPne4MzOzh2NECzPC=>
KPL-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fTN\|ExKM7:TR?=	MmLUO\|IhcA>?	NF22UHlFVVOR	M2rIUmlEPTB;MUCg{txO	M2iydFI{QDR2MEO4
KYSE-30	M4jV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3BNVAh\|ryP	MYK3NkBp	M2rjR2ROW09?	NX7QXFBJUUN3ME2xNEDPxE1?	Mn7jNlM5PDRyM{i=
LNCaP	Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TqS\|ExKM7:TR?=	M2TkZ\|czKGh?	NUX0bJRHTE2VTx?=	NE\5V2xKSzVyPUGwJO69VQ>?	MYiyN\|g1PDB\|OB?=
MCF-7	MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHraSYYyOCEQvF2=	Mo\WO\|IhcA>?	MUnEUXNQ	M37XOWlEPTB;MUCg{txO	M17wUlI{QDR2MEO4
MC-IXC	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWmxNEDPxE1?	MVS3NkBp	MYPEUXNQ	MknrTWM2OD1zMDFOwG0>	MUGyN\|g1PDB\|OB?=
MDA-MB-175 VII	NFLPSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWKxNEDPxE1?	NVf1WIlrPzJiaB?=	M4TneGROW09?	Mn\0TWM2OD1zMDFOwG0>	Mlf2NlM5PDRyM{i=
MDA-MB-468	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXGxNEDPxE1?	NInhW5I4OiCq	NI\YRm1FVVOR	NV30XpVwUUN3ME2xNEDPxE1?	MmrDNlM5PDRyM{i=
MiaPaCa	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rTWFExKM7:TR?=	MUC3NkBp	MY\EUXNQ	M2rueGlEPTB;MUCg{txO	NGD0R2YzOzh2NECzPC=>
Molt-4	M2TKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3WdpNUOTBizszN	M4O3d\|czKGh?	MVfEUXNQ	NHmybndKSzVyPUGwJO69VQ>?	M1LDXlI{QDR2MEO4
NCI-ADR/RES	MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYOxNEDPxE1?	M{\hUFczKGh?	MXzEUXNQ	MWjJR\|UxRTFyIN88US=>	NYXsU3FVOjN6NESwN\|g>
NCI-H69	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPINVAh\|ryP	NH;BTVM4OiCq	MVrEUXNQ	M2j4c2lEPTB;MUCg{txO	NF\BT\|EzOzh2NECzPC=>
NCI-H82	M1H2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvXNVAh\|ryP	MYi3NkBp	NUHEZ4tRTE2VTx?=	NYPyc5dNUUN3ME2xNEDPxE1?	NFP5TFYzOzh2NECzPC=>
NCI-N87	Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzTO4oyOCEQvF2=	MWO3NkBp	M2i2RmROW09?	MmH6TWM2OD1zMDFOwG0>	NYrhZYlxOjN6NESwN\|g>
NCI-H146	NVHQbFZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfseZEyOCEQvF2=	MXi3NkBp	MVXEUXNQ	MYnJR\|UxRTFyIN88US=>	NGLndGYzOzh2NECzPC=>
NCI-H157	M1jZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nQTlExKM7:TR?=	MX[3NkBp	NX\nbXJOTE2VTx?=	NFW4cmZKSzVyPUGwJO69VQ>?	NYfTRXVNOjN6NESwN\|g>
NCI-H187	M1zOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPtNVAh\|ryP	NEPFbGw4OiCq	M4LtZWROW09?	M3rS[WlEPTB;MUCg{txO	MnPZNlM5PDRyM{i=
NCI-H209	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHe3TYQyOCEQvF2=	NXvaPYx7PzJiaB?=	MkTDSG1UVw>?	MWHJR\|UxRTFyIN88US=>	NF7hW\|MzOzh2NECzPC=>
NCI-H226	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLyVokyOCEQvF2=	MVu3NkBp	NG\N[4lFVVOR	NUXkbmlHUUN3ME2xNEDPxE1?	MUWyN\|g1PDB\|OB?=
NCI-H292	M1PN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;xV3kyOCEQvF2=	NIjEbm84OiCq	M3LTRmROW09?	MmXWTWM2OD1zMDFOwG0>	NEj3VIczOzh2NECzPC=>
NCI-H322	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDNdIxIOTBizszN	MWe3NkBp	M3WwOmROW09?	NF3TTZZKSzVyPUGwJO69VQ>?	NFfWe\|AzOzh2NECzPC=>
NCI-H358	M3[0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojaNVAh\|ryP	Mn[yO\|IhcA>?	MX;EUXNQ	NXvqbm1IUUN3ME2xNEDPxE1?	NWT1R3c3OjN6NESwN\|g>
NCI-H520	NFTpUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDPNVAh\|ryP	M3jPXVczKGh?	M1nxWWROW09?	Mkm3TWM2OD1zMDFOwG0>	NG[xe3MzOzh2NECzPC=>
NCI-H526	MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;kOlExKM7:TR?=	NE\Kb484OiCq	MofvSG1UVw>?	NEXX[WlKSzVyPUGwJO69VQ>?	Ml7SNlM5PDRyM{i=
NCI-H630	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWCxNEDPxE1?	MYK3NkBp	MkmzSG1UVw>?	NWTrUWZOUUN3ME2xNEDPxE1?	NHLQcG0zOzh2NECzPC=>
NCI-H661	M{Xzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzrd5cyOCEQvF2=	MUO3NkBp	NHzkUpJFVVOR	NWPveWRnUUN3ME2xNEDPxE1?	MViyN\|g1PDB\|OB?=
NCI-H716	MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfpNVAh\|ryP	M4LCeFczKGh?	MlrISG1UVw>?	MknuTWM2OD1zMDFOwG0>	MlLGNlM5PDRyM{i=
NCI-H1563	M3q3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHNOIc5OTBizszN	M2[yelczKGh?	MYfEUXNQ	MWXJR\|UxRTFyIN88US=>	M3;lW\|I{QDR2MEO4
NCI-H1792	NYTTdXc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PZOFExKM7:TR?=	M3jpNVczKGh?	MWjEUXNQ	NH7xcHhKSzVyPUGwJO69VQ>?	NFXDOogzOzh2NECzPC=>
NCI-H2030	M3qxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHkb\|h3OTBizszN	NXK4RXM4PzJiaB?=	NXy2[mwzTE2VTx?=	M1;LWWlEPTB;MUCg{txO	MnLvNlM5PDRyM{i=
NCI-H2052	NHrKfXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4n2VlExKM7:TR?=	MUm3NkBp	Mn7aSG1UVw>?	M1PXTGlEPTB;MUCg{txO	M3TrZVI{QDR2MEO4
NCI-H2122	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVexNEDPxE1?	NWLGXG1mPzJiaB?=	NYrabW1yTE2VTx?=	M1LMTWlEPTB;MUCg{txO	MkfwNlM5PDRyM{i=
NCI-H2228	M4GxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLrPIwyOCEQvF2=	MlHtO\|IhcA>?	M{OzZmROW09?	NVO5b2NpUUN3ME2xNEDPxE1?	MmmzNlM5PDRyM{i=
OE-19	NYT6ell2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjpUmUyOCEQvF2=	MYG3NkBp	M3j1WGROW09?	MWXJR\|UxRTFyIN88US=>	Mmf3NlM5PDRyM{i=
OE-21	NYjyXHFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{S2R\|ExKM7:TR?=	M2\Gd\|czKGh?	MlLXSG1UVw>?	MUjJR\|UxRTFyIN88US=>	NEju[WwzOzh2NECzPC=>
OE-33	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkL0NVAh\|ryP	M3rnelczKGh?	NU\MT\|lvTE2VTx?=	MlH4TWM2OD1zMDFOwG0>	M1HPZlI{QDR2MEO4
OVCAR-3	NWXwb2dqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33PVlExKM7:TR?=	MnrjO\|IhcA>?	NI[1ZYhFVVOR	NGjNN3JKSzVyPUGwJO69VQ>?	M{HTVFI{QDR2MEO4
OVCAR-4	MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvmNVAh\|ryP	M2qwVFczKGh?	NU\oXGw6TE2VTx?=	MoL5TWM2OD1zMDFOwG0>	NGjkdJczOzh2NECzPC=>
OVCAR-5	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3npTVExKM7:TR?=	NH7GUI84OiCq	NVqxS4dGTE2VTx?=	MWTJR\|UxRTFyIN88US=>	MYWyN\|g1PDB\|OB?=
P3HR-1	M1vtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;n[YVHOTBizszN	MnTpO\|IhcA>?	NV7QcGNjTE2VTx?=	NXzySoJVUUN3ME2xNEDPxE1?	MXuyN\|g1PDB\|OB?=
PC-3	NWXPeHRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3H0WFExKM7:TR?=	MXy3NkBp	MXzEUXNQ	MXPJR\|UxRTFyIN88US=>	M3yyb\|I{QDR2MEO4
Raji	NIK1NWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\GfVExKM7:TR?=	MoWwO\|IhcA>?	M2rrPWROW09?	NGTaeFBKSzVyPUGwJO69VQ>?	MXmyN\|g1PDB\|OB?=
RD	M1\sNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3n0c\|ExKM7:TR?=	Ml;LO\|IhcA>?	M2W1XmROW09?	Mme1TWM2OD1zMDFOwG0>	MX:yN\|g1PDB\|OB?=
RD-ES	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;5UJhwOTBizszN	NE\Ec5M4OiCq	MUTEUXNQ	NYS5S\|ZjUUN3ME2xNEDPxE1?	NX76VWp3OjN6NESwN\|g>
RL	M1r2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnn6NVAh\|ryP	MUO3NkBp	NV7wXnpWTE2VTx?=	NX7FVJd[UUN3ME2xNEDPxE1?	NYX4PZZVOjN6NESwN\|g>
SaOS2	NF;qVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnpVXJJOTBizszN	MWG3NkBp	NEeyclJFVVOR	M{njfGlEPTB;MUCg{txO	NYW3cFEzOjN6NESwN\|g>
SCC-9	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPkZnYyOCEQvF2=	MXO3NkBp	MYnEUXNQ	M3z6eGlEPTB;MUCg{txO	Mn3DNlM5PDRyM{i=
SCC-12	MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLvO4FoOTBizszN	NUexZ2VMPzJiaB?=	MWXEUXNQ	NXfYPZZFUUN3ME2xNEDPxE1?	MVeyN\|g1PDB\|OB?=
SCC-13	M1;vTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjJSXcyOCEQvF2=	NFvxTlc4OiCq	NH\2XmRFVVOR	MVvJR\|UxRTFyIN88US=>	M1;lUlI{QDR2MEO4
SCC-15	M17jemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Ltd\|ExKM7:TR?=	M4XyUFczKGh?	MkS0SG1UVw>?	M{XMemlEPTB;MUCg{txO	NVTaS4Z{OjN6NESwN\|g>
SCC-25	NHW4O5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUD4cXBwOTBizszN	NYPpVpNuPzJiaB?=	NFTW[mFFVVOR	MY\JR\|UxRTFyIN88US=>	NEDVT2IzOzh2NECzPC=>
SCLC-3	NELpOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\yS2cyOCEQvF2=	M4TnVlczKGh?	NEez[45FVVOR	NVLDbpd4UUN3ME2xNEDPxE1?	MWKyN\|g1PDB\|OB?=
SF-268	NFvaZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXju[oM4OTBizszN	NFTtUYk4OiCq	MWXEUXNQ	NUP4XYFFUUN3ME2xNEDPxE1?	Mnf0NlM5PDRyM{i=
SF-295	NWWxTJpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEP1em4yOCEQvF2=	MUe3NkBp	MVjEUXNQ	NHvuSopKSzVyPUGwJO69VQ>?	MWWyN\|g1PDB\|OB?=
SJRH30	NYfQNY54T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3KwOVExKM7:TR?=	NYT5R2pmPzJiaB?=	MkXuSG1UVw>?	MkPtTWM2OD1zMDFOwG0>	NInUNmIzOzh2NECzPC=>
SK-BR-3	NWDydmRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfOV2YyOCEQvF2=	MYK3NkBp	M3X6XWROW09?	MWnJR\|UxRTFyIN88US=>	MmfsNlM5PDRyM{i=
SK-LMS-1	MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYqxNEDPxE1?	NVHPZm1GPzJiaB?=	NGTmcllFVVOR	NED0dIRKSzVyPUGwJO69VQ>?	M1vxNlI{QDR2MEO4
SK-N-DZ	NV32TWo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGi1U4wyOCEQvF2=	NWHHfWt[PzJiaB?=	NELUfIdFVVOR	MVnJR\|UxRTFyIN88US=>	MYmyN\|g1PDB\|OB?=
SK-N-F1	Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mli1NVAh\|ryP	M3npUFczKGh?	NFjPToZFVVOR	M{Drc2lEPTB;MUCg{txO	MVSyN\|g1PDB\|OB?=
SKOV-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHXUY0yOCEQvF2=	M2LOeFczKGh?	NXjiOmRuTE2VTx?=	M2G2NGlEPTB;MUCg{txO	MXmyN\|g1PDB\|OB?=
SK-UT-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVSxNEDPxE1?	NH\NSoY4OiCq	MkjLSG1UVw>?	M36z[mlEPTB;MUCg{txO	NY\wTmxROjN6NESwN\|g>
SN12C	MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDRNVAh\|ryP	MVS3NkBp	Ml\BSG1UVw>?	M4r5U2lEPTB;MUCg{txO	M{\NNlI{QDR2MEO4
SNB-19	Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzkNVAh\|ryP	NV3WRmZSPzJiaB?=	M4jjVWROW09?	NV;iS2d5UUN3ME2xNEDPxE1?	NFfzWIIzOzh2NECzPC=>
SNU-5	NV20bmw1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnyzNVAh\|ryP	M2fUTlczKGh?	NYLhXnZ4TE2VTx?=	NYruPVNDUUN3ME2xNEDPxE1?	NYG3eHNMOjN6NESwN\|g>
SNU-16	Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXyxNEDPxE1?	NIPs[JM4OiCq	M3HYOmROW09?	MUfJR\|UxRTFyIN88US=>	NXLETmR6OjN6NESwN\|g>
SNU-398	MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnG1NVAh\|ryP	MVW3NkBp	NXn3dW1jTE2VTx?=	NU\uUmFyUUN3ME2xNEDPxE1?	M4fzOlI{QDR2MEO4
SNU-449	M2m1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV2xNEDPxE1?	M1n4[lczKGh?	M4O3UmROW09?	NXf2TWI6UUN3ME2xNEDPxE1?	NX[zOZVROjN6NESwN\|g>
SR	MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\SNFExKM7:TR?=	NXHiZmZ5PzJiaB?=	NIS2SJNFVVOR	MW\JR\|UxRTFyIN88US=>	MV6yN\|g1PDB\|OB?=
ST486	MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XjWlExKM7:TR?=	MknIO\|IhcA>?	M4rEPGROW09?	NIny[pVKSzVyPUGwJO69VQ>?	MVuyN\|g1PDB\|OB?=
SW579	NGPpVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfMV3pWOTBizszN	M1SyUVczKGh?	M1;DNWROW09?	M2LxOGlEPTB;MUCg{txO	M2mybVI{QDR2MEO4
SW684	M4TtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{S2bFExKM7:TR?=	NIHhN\|Y4OiCq	MUTEUXNQ	M3TOWmlEPTB;MUCg{txO	NVfOTo9tOjN6NESwN\|g>
SW-780	NEW2NG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUOxNEDPxE1?	MY[3NkBp	NYi3WnJyTE2VTx?=	MXPJR\|UxRTFyIN88US=>	NXTnTYdwOjN6NESwN\|g>
SW900	Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;aNVAh\|ryP	NX7rfZk{PzJiaB?=	MYjEUXNQ	M3jV[WlEPTB;MUCg{txO	MlL4NlM5PDRyM{i=
SW1088	NEC4eVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVuxNEDPxE1?	NUfUZZZSPzJiaB?=	Ml64SG1UVw>?	NY\BSFVoUUN3ME2xNEDPxE1?	MmDYNlM5PDRyM{i=
SW1463	MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrreXAyOCEQvF2=	MkH1O\|IhcA>?	NGfRVnBFVVOR	NGXSXlVKSzVyPUGwJO69VQ>?	NGiz[pczOzh2NECzPC=>
SW1990	NXHyTpR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIriVJgyOCEQvF2=	M3q5eVczKGh?	NX;tSZlyTE2VTx?=	NFfBU4pKSzVyPUGwJO69VQ>?	NV;pe2pJOjN6NESwN\|g>
T47D	NX3NTI1[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnmNFMyOCEQvF2=	MWS3NkBp	MnLaSG1UVw>?	M4nvcGlEPTB;MUCg{txO	NGq4[XIzOzh2NECzPC=>
TE381.T	NHu4XHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUSxNEDPxE1?	NIfTSWY4OiCq	MV;EUXNQ	M2\tRWlEPTB;MUCg{txO	NIDwVpAzOzh2NECzPC=>
TK-10	NIfZTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXNTm9qOTBizszN	NXu3e28xPzJiaB?=	NYDOV3dwTE2VTx?=	MWjJR\|UxRTFyIN88US=>	MkHCNlM5PDRyM{i=
U2OS	MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF[1cFkyOCEQvF2=	MoHMO\|IhcA>?	NVPnVmF3TE2VTx?=	NXLTRnd4UUN3ME2xNEDPxE1?	NFr4WJUzOzh2NECzPC=>
U251	MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXmxNEDPxE1?	M3rDTlczKGh?	MWTEUXNQ	MVjJR\|UxRTFyIN88US=>	MX2yN\|g1PDB\|OB?=
UACC-812	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVH0eoxPOTBizszN	NHv4O\|E4OiCq	NH;3WHNFVVOR	MW\JR\|UxRTFyIN88US=>	M4qwUFI{QDR2MEO4
YAPC	MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmT2NVAh\|ryP	NWDXO5IxPzJiaB?=	MlXwSG1UVw>?	NGXHcllKSzVyPUGwJO69VQ>?	MmnhNlM5PDRyM{i=
ZR-75-1	NEW1WJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXuxNEDPxE1?	NIPGfHY4OiCq	MVTEUXNQ	M3q3bmlEPTB;MUCg{txO	NEXpdmwzOzh2NECzPC=>
A375	M1O2WWZ2dmO2aX;uJIF{e2G7	NUTZO20yOS5{IN88US=>	NGPmVYg1KGh?	NITHV2VFVVOR	M3XjR2lvcGmkaYTpc44hd2ZicHjvd5Bpd3K7bHH0bY9vKG:oIF3FT{whTVKNLDDhcoQhWz[S	NFO0b48zOjN6OUS3NS=>
YUSIT1	MoWxSpVv[3Srb36gZZN{[Xl?			M4HDRWROW09?	MWLy[YR2[2WmIIPlcpNqfGm4aYT5JJdqfGhiSVO1NEA,KDBwNTFOwG0>	M{LMbVIzOzh7NEex
MeWo	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NVLnXpJGTE2VTx?=	MknzTWM2OCB;IEm4O{BvVQ>?	M3HxPFI3ODF6NUK0
WiDr	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NFW5NYlFVVOR	MXnJR\|UxKD1iN{[gcm0>	MWqyOlAyQDV{NB?=
Colo-205	NV\3PFhyTnWwY4Tpc44h[XO\|YYm=	NHnzdlgyKM7:TR?=	NV7yUJpqPCCm	M1jHPWROW09?	NW\4eFI5UW6mdXPl[EBiKGirZ3jsfUBkd22yYYLhZoxmKGOxbYDhZ5Rqd25icHjlco91gXCn	MV[yOVM5OTF3Mh?=
RBW-1	MofJSpVv[3Srb36gZZN{[Xl?	NULueFFGOSEQvF2=		MVzEUXNQ	NY\iT4RRVm9icnXkeYN1cW:wIH;mJG1mcyBzL{KgdIhwe3Cqb4L5cIF1cW:w	NE\KTpczPDh6NU[5NC=>
RBO-1	M1nkNGZ2dmO2aX;uJIF{e2G7	NIfFVY4yKM7:TR?=		M4T1bGROW09?	NUnwfHV1UW6qaXLpeIlwdiCxZjDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	M3\EWVI1QDh3Nkmw
RBO-2	NUXsS3BoTnWwY4Tpc44h[XO\|YYm=	NEXRTmQyKM7:TR?=		MWLEUXNQ	MnK2TY5pcWKrdHnvckBw\iBiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	M4XhVVI1QDh3Nkmw
RBOW	MkTwSpVv[3Srb36gZZN{[Xl?	M3faTlEh\|ryP		NGDNUodFVVOR	NGXGellKdmirYnn0bY9vKG:oIDDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	MlvMNlQ5QDV4OUC=
M257	NGjRXWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrIZWMyODBibl2=	MXO3NkBp		NGP6TnVFd2W\|IH7veEBqdmirYnn0JJBzd2yrZnXyZZRqd25ib3[gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[=	Mom2NlM{OTd2NE[=
LCP	MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFH5OJIyODBibl2=	MlzwO\|IhcA>?		NWrYZlNYUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>?	NGrsWmszOzNzN{S0Oi=>
WM266	NUTuO5ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXoNVAxKG6P	MmPuO\|IhcA>?		MXvJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhX01{Nk[gZ4VtdCCqYYLic5VzcW6pIFLSRWYhXjZyMVSgcZV1[W62YYTpc44>	NIfDWYszOzNzN{S0Oi=>
M257	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTDfosxOTByIH7N	MlHOO\|IhcA>?		NXm1fmoyTG:nczDuc5QhcW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJG0zPTdiY3XscEBp[XKkb4XybY5oKHerbHSgeJlx\SCEUlHG	MWWyN\|MyPzR2Nh?=
LCP	NYLsfZdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjkXVdUOTByIH7N	NYXJU4ZpPzJiaB?=		MmrkTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>?	MWWyN\|MyPzR2Nh?=
WM266	NGS5XXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvDdnYyODBibl2=	NYHXTmJ[PzJiaB?=		M3faWWlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDXUVI3PiClZXzsJIhiemKxdYLpcochSlKDRjDWOlAxTCCvdYThcpRifGmxbh?=	MXeyN\|MyPzR2Nh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pMEK / pERK / ERK; PubMed: 31158244 PLoS One Cell lines as shown were treated with dabrafenib, over a dose range, for 1 hour. UT = untransfected. Expression and/or phosphorylation of the indicated proteins were assessed by immunoblot. p-S6 / p-AKT308 / p-AKT473; PubMed: 24735930 Mol Cancer Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib. β-catenin; PubMed: 29167314 Mol Cancer Ther HT-29 cells were treated with BRAF inhibitors Dabrafenib (2 μM), GDC-0879 (4 μM) or Vemurafenib (2 μM) for indicated times. The whole cell lysates were used for western blot with indicated antibodies.	31158244 24735930 29167314
Growth inhibition assay	IC50; PubMed: 24735930 Mol Cancer A panel of 23 BRAF(V600) mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM.	24735930

In vivo

Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. ^[1]

Protocol

References

Solubility (25°C)

In vitro	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+45% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dabrafenib (GSK2118436) SDF

Molecular Weight	519.56
Formula	C₂₃H₂₀F₃N₅O₂S₂
CAS No.	1195765-45-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04452877	Not yet recruiting	Drug: Dabrafenib\|Drug: Trametinib	Carcinoma Non-Small-Cell Lung	Novartis Pharmaceuticals\|Novartis	August 31 2020	Phase 2
NCT04059224	Recruiting	Drug: Trametinib\|Drug: Dabrafenib	Stage IV Melanoma\|Stage III Melanoma	Universitair Ziekenhuis Brussel	January 28 2019	Phase 2
NCT03668431	Recruiting	Drug: Dabrafenib\|Drug: Trametinib\|Drug: PDR001	Metastatic Colorectal Cancer	Massachusetts General Hospital\|Novartis\|Stand Up To Cancer	October 15 2018	Phase 2
NCT03553329	Completed	Drug: dabrafenib	Unresecable Stage IIIc or IV Melanoma	Poitiers University Hospital	June 2 2018	--
NCT03593993	Recruiting	Procedure: Surgical Cohort	Glioma\|BRAF V600E\|Pleomorphic Xantho-Astrocytoma\|Glioblastoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Musella Foundation	May 19 2018	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Pan Raf Inhibitor

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA-approved Raf Inhibitor

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
Newest Raf Inhibitor

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Related Raf Products

LY3009120 ^New

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. LY03009120 induces autophagy. Phase 1.
Ravoxertinib (GDC-0994) ^New

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523) ^New

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032)

Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold. Vemurafenib (PLX4032, RG7204) induces autophagy.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Sorafenib

Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Sorafenib Tosylate

Sorafenib Tosylate (Bay 43-9006) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
PLX-4720

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
TAK-632

TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
GDC-0879

GDC-0879 (AR-00341677) is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.
GW5074

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted. GW5074 inhibits LK-induced apoptosis.

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)